Opinion|Videos|April 22, 2024
Treating Residual Disease in Upper GI Cancers Following FLOT Treatment
The Oncology Brothers and Sam Klempner, MD, offer comprehensive insights on treating residual disease in upper GI cancers following FLOT treatment.
Advertisement
Advertisement
Related to this article
Lutetium Lu 177 dotatate injection has been approved by the FDA for patients with somatostatin receptor-positive GEP-NETs.
A GDNS protocol did not significantly reduce loss of ASMI compared with usual care during chemoradiotherapy following esophagectomy in esophageal cancer.
Advertisement
Advertisement
Trending on CancerNetwork
1
Key Takeaways for Multidisciplinary Lung Cancer Care From WCLC 2026
2
CELMoDs After T-Cell–Engaging Therapy in Multiple Myeloma
3
Pembrolizumab/Enfortumab Vedotin Earns Positive CHMP Opinion in MIBC
4
FDA Approves Imlunestrant Combo in ESR1-Mutated Breast Cancer
5